Maravai LifeSciences Holdings, Inc. (MRVI) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MRVI Revenue Growth
Revenue Breakdown (FY 2025)
MRVI's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
MRVI Revenue Analysis (2018–2025)
As of May 8, 2026, Maravai LifeSciences Holdings, Inc. (MRVI) generated trailing twelve-month (TTM) revenue of $185.7 million, reflecting significant decline in growth of -11.6% year-over-year. The most recent quarter (Q4 2025) recorded $49.9 million in revenue, up 19.8% sequentially.
Looking at the longer-term picture, MRVI's 5-year compound annual growth rate (CAGR) stands at -29.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $883.0 million in 2022.
Revenue diversification analysis shows MRVI's business is primarily driven by Shipping and Handling (100%). With over half of revenue concentrated in Shipping and Handling, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AZTA (+1.8% YoY), BCAB (-81.8% YoY), and ALNY (+82.6% YoY), MRVI has underperformed the peer group in terms of revenue growth. Compare MRVI vs AZTA →
MRVI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MRVICurrent | $186M | -11.6% | -29.4% | -431.7% | |
 AZTA | $594M | +1.8% | +8.9% | -1.9% | |
 BCAB | $2M | -81.8% | +36.1% | -2965.3% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
MRVI Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $49.9M | -80.8% | $12.8M | 25.8% | $-215,266,000 | -431.7% |
| 2024 | $259.2M | -10.3% | $108.3M | 41.8% | $-235,617,000 | -90.9% |
| 2023 | $288.9M | -67.3% | $140.2M | 48.5% | $-31,648,000 | -11.0% |
| 2022 | $883.0M | +10.5% | $714.0M | 80.9% | $574.2M | 65.0% |
| 2021 | $799.2M | +181.3% | $658.7M | 82.4% | $554.6M | 69.4% |
| 2020 | $284.1M | +98.5% | $204.4M | 72.0% | $119.9M | 42.2% |
| 2019 | $143.1M | +15.6% | $76.3M | 53.3% | $24.0M | 16.8% |
| 2018 | $123.8M | - | $63.1M | 50.9% | $16.4M | 13.3% |
See MRVI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRVI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRVI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMRVI — Frequently Asked Questions
Quick answers to the most common questions about buying MRVI stock.
Is MRVI's revenue growth accelerating or slowing?
MRVI revenue declined -11.6% year-over-year, contrasting with the 5-year CAGR of -29.4%. TTM revenue fell to $186M. This reverses the prior growth trend.
What is MRVI's long-term revenue growth rate?
Maravai LifeSciences Holdings, Inc.'s 5-year revenue CAGR of -29.4% reflects the variable expansion pattern. Current YoY growth of -11.6% is below this long-term average.
How is MRVI's revenue distributed by segment?
MRVI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.